The UK medicines regulator has awarded two key licences to the Cell and Gene Therapy Catapult in Stevenage, a £60m ($79m) government-funded initiative which opened last year. The licences, granted by the UK’s Medicines and Stevenage, mean biotechs using the facility can develop commercial medicines for patient use or to support clinical trials.
The UK medicines regulator has awarded two key licences to the Cell and Gene Therapy Catapult in Stevenage, a £60m ($79m) government-funded initiative which opened last year. The licences, granted by the UK’s Medicines and Healthcare Products Regulatory Agency, mean biotechs using the facility can develop commercial medicines for patient use or to support clinical trials.